

ASX RELEASE

30 April 2018

## 4C Quarterly Cash Flow Report

Innate Immunotherapeutics Limited (ASX Code: IIL) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 31 March 2018.

The cash balance as at 31 March 2018 was \$2,229,000, a decrease of \$519,000 from the end of the previous quarter.

The total estimated cash outflow for the quarter ending 30 June is \$347,000. The cash outflow includes staff costs of \$257,000 of which \$151,000 relate to final redundancies and related payments which are a non-recurring cost.

The total estimated outflow of \$347,000 is a net amount after taking into account a one-off cash refund of \$220,000 received during April. This refund was due to the Company following the final reconciliation of payments previously made to the Clinical Research Organisation responsible for the management of the Company's Phase 2B trial last year. The refund offsets an expected \$50,000 research and development cash outflow during the quarter, resulting in a net R&D cash credit of \$170,000.

On 26 April 2018, shareholder approval was obtained for the acquisition of 100% of the issued capital of Amplia Therapeutics Pty Limited in consideration for the issue of 18,460,308 shares in Innate Immunotherapeutics. The shares are to be issued post the 1 for 10 share consolidation also approved on 26 April. It is expected that the Amplia acquisition will be settled on or about 3 May 2018.

The estimated cash outflow for the quarter ending 30 June includes costs associated with the Amplia acquisition as well as costs associated with the commencement of development activities relating to the Amplia drug candidates.

- End

### For Further Information

Simon Wilkinson, CEO

+64 21 661 850

[www.innateimmuno.com](http://www.innateimmuno.com)

Suite 401, 35 Lime Street, Sydney 2000, Australia

Phone: +61 2 8003 3650

Email [info@innateimmuno.com](mailto:info@innateimmuno.com)

[www.innateimmuno.com](http://www.innateimmuno.com)

## Appendix 4C

### Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

**Name of entity**

Innate Immunotherapeutics Limited

**ABN**

16 165 160 841

**Quarter ended ("current quarter")**

31 March 2018

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers		
1.2 Payments for		
(a) research and development	<11>	<3,095>
(b) product manufacturing and operating costs		
(c) advertising and marketing		
(d) leased assets		
(e) staff costs	<419>	<1,580>
(f) administration and corporate costs	<82>	<679>
1.3 Dividends received (see note 3)		
1.4 Interest received	1	28
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives	-	1,849
1.8 Other (provide details if material)	<39>	<72>
<b>1.9 Net cash from / (used in) operating activities</b>	<b>&lt;550&gt;</b>	<b>&lt;3,549&gt;</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) property, plant and equipment	-	<4>
(b) businesses (see item 10)		
(c) investments		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
(d) intellectual property		
(e) other non-current assets		
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	6
(b) businesses (see item 10)		
(c) investments		
(d) intellectual property		
(e) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material)		
<b>2.6 Net cash from / (used in) investing activities</b>	<b>-</b>	<b>2</b>

<b>3. Cash flows from financing activities</b>		
3.1 Proceeds from issues of shares		
3.2 Proceeds from issue of convertible notes		
3.3 Proceeds from exercise of share options		
3.4 Transaction costs related to issues of shares, convertible notes or options	-	<13>
3.5 Proceeds from borrowings		
3.6 Repayment of borrowings		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other (provide details if material)		
<b>3.10 Net cash from / (used in) financing activities</b>	<b>-</b>	<b>&lt;13&gt;</b>

<b>4. Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1 Cash and cash equivalents at beginning of quarter/year to date	2,748	5,763
4.2 Net cash from / (used in) operating activities (item 1.9 above)	<550>	<3,549>
4.3 Net cash from / (used in) investing activities (item 2.6 above)	-	2
4.4 Net cash from / (used in) financing activities (item 3.10 above)	-	<13>

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (12 months) \$A'000</b>
4.5	Effect of movement in exchange rates on cash held	31	26
<b>4.6</b>	<b>Cash and cash equivalents at end of quarter</b>	<b>2,229</b>	<b>2,229</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	296	1,823
5.2	Call deposits	1,933	925
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>2,229</b>	<b>2,748</b>

**6. Payments to directors of the entity and their associates**

- 6.1 Aggregate amount of payments to these parties included in item 1.2
- 6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

<b>Current quarter \$A'000</b>
93
-

This item includes payment of directors fees to Non-executive Directors A\$42,500 (6 months) plus the CEO remuneration payment for the quarter of NZ\$53,077 (i.e. A\$50,387).

**7. Payments to related entities of the entity and their associates**

- 7.1 Aggregate amount of payments to these parties included in item 1.2
- 7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3
- 7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

<b>Current quarter \$A'000</b>
-
-

8. <b>Financing facilities available</b> <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities		
8.2 Credit standby arrangements		
8.3 Other (please specify)		
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--

9. <b>Estimated cash outflows for next quarter</b>	\$A'000
9.1 Research and development	170
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	<257>
9.6 Administration and corporate costs	<230>
9.7 Other (Costs associated with acquisition of Amplia Therapeutics Pty Limited)	<30>
<b>9.8 Total estimated cash outflows</b>	<b>&lt;347&gt;</b>

10. <b>Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)</b>	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

### Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Sign here:

  
Simon Wilkinson  
(Director/Company secretary)

Date: 30 April 2018

Print name: .Simon Wilkinson

### Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.